ORA - Oxford University Research Archive

1 - 26 of 26

1

Conference

EXPERIENCE FROM A MULTI-DISCIPLINARY DEDICATED HAND OSTEOARTHRITIS CLINIC: THE ROLE OF CORTICOSTEROID INTRA-ARTICULAR INJECTION AS PART OF AN INDIVIDUALISED TREATMENT PROGRAMME

Watt, F, Kennedy, D, Seymour, M, et al.
2010-10-05

2

Conference

THROMBOCYTOSIS AS A PREDICTIVE AND PROGNOSTIC MARKER IN ADVANCED COLORECTAL CANCER (ACRC): RESULTS OF THE MRC COIN TRIAL EXPLORED

Maughan, T, Wilson, R, Seymour, M, et al.
2010-10-05

3

Journal article

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial

Adams, R, Brown, E, Brown, L, et al.
2017

4

Journal article

Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.

Rosmarin, D, Palles, C, Church, D, et al.
2014-04-05

5

Conference

Mismatch Repair Testing in Colorectal Cancer - Is Less More?

Hutchins, G, Southward, K, Handley, K, et al.
2012-03-05

6

Conference

KRAS and BRAF Mutational Status can be Accurately Determined on Diagnostic Tissue Biopsies: An Analysis of Matched Biopsy and Resection Material from Patients with Colon Cancer in the NCRI FOxTROT trial

West, N, Hemmings, GJ, Richman, SD, et al.
2012-03-05

7

Journal article

Chemotherapy-free intervals for patients with metastatic colorectal cancer remain an option.

Maughan, T, Adams, R, Wilson, R, et al.
2010-06-05

8

Journal article

Ultrasonographic measures of synovitis in an early phase clinical trial: a double-blind, randomised, placebo and comparator controlled phase IIa trial of GW274150 (a selective inducible nitric oxide synthase inhibitor) in rheumatoid arthritis.

Seymour, M, Pétavy, F, Chiesa, F, et al.
2012

9

Journal article

Response.

Smith, CG, West, H, Harris, R, et al.
2014-05-05

10

Journal article

A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: Results of the Panitumumab, Irinotecan and Ciclosporin in COLOrectal cancer therapy trial (PICCOLO)

Middleton, G, Brown, S, Lowe, C, et al.
2013-11-05

11

Journal article

A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan and Ciclosporin in COLOrectal cancer therapy trial (PICCOLO).

Middleton, G, Brown, S, Lowe, C, et al.
2013-11-05

12

Conference

INTERMITTENT VS. CONTINUOUS OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN THE MRC COIN TRIAL IN ADVANCED COLORECTAL CANCER: UPDATED EFFICACY RESULTS, QUALITY OF LIFE AND POTENTIAL PREDICTIVE FACTORS

Adams, R, Wilson, R, Seymour, M, et al.
2010

13

Journal article

Role of the oxidative DNA damage repair gene OGG1 in colorectal tumorigenesis.

Smith, CG, West, H, Harris, R, et al.
2013-08-05

14

Journal article

Articular ultrasonography in rheumatoid arthritis

Seymour, M, Taylor, PC
2009

15

Journal article

Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial

Morton, UKD, Seymour, M, Magill, L, et al.
2012-11-05

16

Conference

Histopathological Downstaging of Colon Cancer Following Six Weeks of Pre-operative Chemotherapy: Early Results of the NCRI FOxTROT Trial

West, N, Tinkler-Hundal, E, Handley, K, et al.
2012-03-05

17

Conference

THE ADDITION OF CETUXIMAB TO OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN FIRST-LINE ADVANCED COLORECTAL CANCER IN THE MRC COIN TRIAL: IDENTIFICATION OF POTENTIALLY RESPONSIVE SUBSETS OF PATIENTS

Maughan, T, Adams, R, Smith, C, et al.
2010

18

Journal article

ADDITION OF CETUXIMAB TO OXALIPLATIN-BASED COMBINATION CHEMOTHERAPY (CT) IN PATIENTS WITH K-ras WILD-TYPE ADVANCED COLORECTAL CANCER (ACRC): EFFECTS ON OVERALL SURVIVAL. MRC COIN (CR10) TRIAL RESULTS

Adams, R, Maughan, T, Smith, C, et al.
2009

19

Journal article

Intra-tumoural stromal morphometry predicts disease recurrence but not response to 5-fluorouracil - results from the QUASAR trial of colorectal cancer.

Hutchins, GGA, Treanor, D, Wright, A, et al.
2017-07-26

20

Book section

The Face of the Assyrian Empire: Mythology and the Heroic King

Collins, PT
2016-12-30

21

Conference

THE IMPACT OF MILD RENAL IMPAIRMENT ON THE TOXICITY OF OXALIPLATIN AND FLUOROPYRIMIDINE REGIMENS: EXPERIENCE IN THE MRC COIN TRIAL

Madi, A, Wilson, R, Adams, R, et al.
2010

22

Journal article

Accuracy of radiological staging in identifying high-risk colon cancer patients suitable for neoadjuvant chemotherapy: a multicentre experience.

Dighe, S, Swift, I, Magill, L, et al.
2012-04-05

23

Conference

QCD

Nason, P, Webber, BR, Ward, D, et al.
1996

24

Journal article

Quantitative power Doppler ultrasonography is a sensitive measure of metacarpophalangeal joint synovial vascularity in rheumatoid arthritis and declines significantly following a 2-week course of oral low-dose corticosteroids.

Larché, MJ, Seymour, M, Lim, A, et al.
2010-12-05

25

Journal article

Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials

Seligmann, JF, Fisher, D, Smith, CG, et al.
2016-12-19

26

Conference item

FOCUS4-D: Results from a randomised, placebo controlled trial (RCT) of AZD8931 (an inhibitor of signalling by HER1, 2, and 3) in patients (pts) with advanced or metastatic colorectal cancer (aCRC) in tumours that are wildtype (wt) for BRAF, PIK3CA, KRAS and NRAS

conference abstract
Adams, RA, Brown, E, Brown, L, et al.
2016-10-11

TO TOP